Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology's stock price has declined by 29.83% over the past six months. Key events impacting the stock include earnings reports, clinical trial updates with positive data from the Phase 2 CRDF-004 trial, an executive leadership team transition, and preclinical data presentation. Historically, earnings and business updates highlighting clinical progress have often been followed by volatile or negative next-day stock movements, despite positive operational commentary.

As a clinical-stage biotechnology company, Cardiff Oncology, Inc. does not have traditional demand seasonality for its products or services. The company's activities are focused on research and clinical development, and its revenue is generated from royalties and interest income.

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies using PLK1 inhibition. Their primary product candidate, onvansertib, is being evaluated in clinical trials for various cancer indications in combination with standard-of-care therapeutics. The company's revenue is currently generated from royalties and interest income.

Cardiff Oncology, Inc. operates solely within the United States and is headquartered in San Diego, California.

Cardiff Oncology's brand reputation is driven by its clinical progress and analyst sentiment. The company has a consensus rating of "Moderate Buy" or "Strong Buy" from analysts. Positive clinical trial data, strategic leadership appointments, and presentations at scientific meetings contribute to its reputation. There haven't been widely reported specific events that have negatively impacted Cardiff Oncology's brand reputation beyond the inherent risks associated with clinical-stage biotechnology companies.

Cardiff Oncology, Inc. has a mixed ownership structure, including institutional, retail, and individual investors. Approximately 29.00% of the company's stock is owned by Institutional Investors, 4.17% by Insiders, and 66.82% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Key individual and insider owners include Robert Merrill Hunter and Ra Capital Management LP.